SynAct Pharma Q1 2025: New Phase II Study in Dengue Fever - Redeye
Bildkälla: Stockfoto

SynAct Pharma Q1 2025: New Phase II Study in Dengue Fever - Redeye

Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents. Costs increased compared with Q4 2024.

Redeye comments on SynAct's Q1 report, which includes the initiation of a new phase II study in Dengue fever and new patents. Costs increased compared with Q4 2024.
Börsvärldens nyhetsbrev